Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT05142501
  4. Details
NCT05142501 Clinical Trial

Observation of the Immune Response After COVID-19 Additional Vaccine Doses in Chronic Patients in Hemodialysis Therapy

COVID-19 Clinical Trial

— COVID-thIRd  

Official title:
Observation of Humoral and Cellular Immune Response After Additional Vaccine Dose With Different COVID-19 Vaccines in ESKD Patients in Hemodialysis Therapy

Clinical Trial Details — Status: Terminated

Administrative data
NCT number NCT05142501
Other study ID # HD-COVID-IR-EU
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date April 25, 2022
Est. completion date September 2, 2022

Study information
Verified date September 2022
Source Fresenius Medical Care Deutschland GmbH
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Observation of humoral and cellular immune response after additional dose vaccine with different COVID-19 vaccines in ESKD patients in hemodialysis therapy.

Description:

In this open, prospective, observational trial the humoral and cellular immune response in ESKD patients undergoing hemodialysis shall be analyzed after administration of a fourth dose of vaccine. The total follow-up time per patient is up to 12 months after the fourth dose of vaccine. In total, 340 patients (170 patients per country) shall be included. Only adult patients capable of giving consent will be enrolled. The humoral immune response will be analyzed in all patients, whereas the analysis of the cellular immune response will only be conducted in 15% of the enrolled patients. The HD-COVID-IR-EU study shall be conducted in Portugal and in Spain.

Recruitment information / eligibility
Status Terminated
Enrollment 23
Est. completion date September 2, 2022
Est. primary completion date September 2, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Informed consent signed and dated by study patient and investigator/authorized physician - Minimum age of 18 years - Ability to understand the nature and requirements of the study - ESKD patients on maintenance hemodialysis with a minimum of 4hrs three times a week at the time of recruitment and a dialysis vintage =3 months in NC clinics - Patients that already received three doses against COVID-19 as detailed in the manufacturer's instructions - Patients that are scheduled to receive a fourth vaccine dose of either Comirnaty (BioNTech/Pfizer) or Spikevax (Moderna) after approval of respective national authority. Exclusion Criteria: - Any conditions which could interfere with the patient's ability to comply with the study - Participation in an interventional clinical study during the preceding 30 days - Previous participation in the same study - Patients with proven current COVID-19 infection as identified by routine clinical practice - Patient in therapy with immunosuppressive medications / immunomodulators - Patients who already received a fourth COVID-19 vaccination dose

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Blood samples
Four consecutive blood sampling throughout the overall follow-up period of 12 months.

Locations
Country Name City State
Portugal NephroCare Amadora Amadora
Portugal NephroCare Lumiar Lisboa
Portugal NephroCare Restelo Lisboa
Portugal NephroCare Vila Franca de Xira Vila Franca De Xira
Spain Centro de Diálisis Barcelona - Glories Barcelona
Spain Centro de Diálisis Barcelona - Rosselló Barcelona
Spain Centro de Diálisis Granollers Granollers
Spain Centro de Diálisis Dialcentro Madrid
Spain Centro de Diálisis San Luciano Madrid
Spain Centro de Diálisis Sant Boi Sant Boi de Llobregat
Spain Centro de Diálisis Terrassa Terrassa

Sponsors (1)
Lead Sponsor Collaborator
Fresenius Medical Care Deutschland GmbH

Countries where clinical trial is conducted

Portugal,  Spain, 

Outcome
Type Measure Description Time frame Safety issue
Primary Humoral immune response The humoral immune response will be assessed at four different timepoints (Sample 1: prior to the fourth vaccine dose; sample 2: 1 months after the fourth vaccine dose; sample 3: 6 months after the fourth vaccine dose; sample 4: 12 months after the fourth vaccine dose or max. 4 weeks prior to the fifth vaccine dose, whichever comes first) through the measurement of the titers of Bioplex IgG antibody panel in study participant's blood samples. 12 months after start of study
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure